These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 10343002)

  • 21. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DPS--the PMA perspective.
    Beary JF; Cleveland CB
    Am Pharm; 1992 May; NS32(5):6, 8. PubMed ID: 1590210
    [No Abstract]   [Full Text] [Related]  

  • 23. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 24. The effectiveness of generic agents in psychopharmacologic treatment.
    Kumet R; Gelenberg AJ
    Essent Psychopharmacol; 2005; 6(2):104-11. PubMed ID: 15765794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the bioequivalence of generic versus branded clozapine.
    Ereshefsky L; Glazer WM
    J Clin Psychiatry; 2001; 62 Suppl 5():25-7. PubMed ID: 11305845
    [No Abstract]   [Full Text] [Related]  

  • 26. The Hatch-Waxman Act: balancing competing interests or survival of the fittest?
    Behrendt KE
    Food Drug Law J; 2002; 57(2):247-71. PubMed ID: 12436990
    [No Abstract]   [Full Text] [Related]  

  • 27. Look-alike drugs and unfair competition. An update of Inwood Laboratories v. Ives Laboratories.
    Shapiro LJ
    Am Pharm; 1985 Oct; NS25(10):49-50. PubMed ID: 4061279
    [No Abstract]   [Full Text] [Related]  

  • 28. Generic and alternative brand-name pharmaceutical equivalents: select with caution.
    Hendeles L; Hochhaus G; Kazerounian S
    Am J Hosp Pharm; 1993 Feb; 50(2):323-9. PubMed ID: 8480793
    [No Abstract]   [Full Text] [Related]  

  • 29. Wellbutrin versus generic bupropion.
    Med Lett Drugs Ther; 2008 Jul; 50(1290):54-5. PubMed ID: 18617874
    [No Abstract]   [Full Text] [Related]  

  • 30. Avoiding potential pitfalls of generic substitution.
    Zarowitz BJ; Semla T
    Geriatr Nurs; 2009; 30(4):260-3. PubMed ID: 19665668
    [No Abstract]   [Full Text] [Related]  

  • 31. Generic substitution: issues for problematic drugs.
    Henderson JD; Esham RH
    South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment: Pharmacy and generic substitution of antiepileptic drugs: missing in action?
    Hatton RC
    Ann Pharmacother; 2007 Sep; 41(9):1550-1; author reply 1551-2. PubMed ID: 17652128
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacist compounding of analgesic medication: the risk of a little-known practice.
    Johnson P; Jones G
    J Fla Med Assoc; 1997 Jan; 84(1):13-5. PubMed ID: 9037992
    [No Abstract]   [Full Text] [Related]  

  • 34. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmaceuticals: the banning of "tested" generic drugs from India; the first 3D tablet].
    Nau JY
    Rev Med Suisse; 2015 Aug; 11(482):1506-7. PubMed ID: 26449106
    [No Abstract]   [Full Text] [Related]  

  • 38. Plugs for drugs.
    Masson A; Rubin PH
    Regulation; 1986; 10(1):37-43, 53. PubMed ID: 10280556
    [No Abstract]   [Full Text] [Related]  

  • 39. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 40. Bioequivalence/bioavailability retention samples.
    Ransom C
    Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.